- SFG FRC 2027 | Program starts from 19th Dec. 2026 | Admissions open for Entrance Test Click Here to know more →
- Prelims Test Series (PTS) for Prelims 2027 starts 11th Oct. 2026 Click Here to know more →
- [Pre-order] Ethics Redbook 3rd Edition: Delivery starts from 10th October onwards Click Here to Read More →
- 21 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 11th Oct. Click Here to Read More →
What is the news?
Indian Council of Medical Research (ICMR) has approved a kit named OmiSure. It will be used to detect Omicron.
What is OmiSure?
The kit is manufactured by Tata Medical and Diagnostics.
The kit will be used to confirm Omicron in patients with its S-Gene Target Failure (SGTF) strategy.
What are S-Gene Target Failure (SGTF) cases?
The Covid-19 tests such as RT-PCR target “multiple genes” of the virus so that a broad range of variants are covered.
For example, ‘S’ Gene, ORF, ‘N’ gene, ‘E’ gene etc are viral genes that are targeted to detect COVID-19 virus.
In case of the Omicron variant, the ‘S’ gene is not getting detected in RT-PCR test due to mutation in the gene while other gene targets are getting detected. This occurrence is called ‘S’ Gene Target Failure (SGTF) positive cases. Such samples can be presumptively reported as Omicron positive.
Other News Covered in the Article
WHO to setup SARS-CoV-2 Genomics Consortium
WHO is proposing to set up a SARS-CoV-2 genomics consortium in Southeast Asia. The consortium will help enhance genomic sequencing and surveillance.
This will also help improve the timely use of genomic data for public health decision-making and to strengthen preparedness and response to future outbreaks/ pandemics.
Source: This post is based on the article ‘ICMR approves indigenous kit to detect Omicron’ published in The Hindu on 5th Jan 2022.
